A study on telehealth medication abortion in the USA found that it is effective and safe, with 97.7% of abortions being complete without further intervention. The study followed 6,034 patients who obtained medication abortion via telehealth from three virtual clinics across 20 states and Washington, DC. Safety was measured by the absence of serious adverse events, with 99.8% of abortions not resulting in such events. The effectiveness and safety were similar between synchronous and asynchronous models of care. The study also found that telehealth medication abortion is comparable to in-person care in terms of effectiveness and safety. The FDA removed the requirement for in-person dispensing of mifepristone in 2021, allowing for telehealth medication abortion. The study highlights the importance of telehealth in meeting increased demand for abortion care, especially in states with abortion bans. However, access to mifepristone is under threat, with a federal court ruling to reverse FDA regulatory approvals. The study also found that Black patients had higher rates of serious adverse events than white patients, highlighting disparities in obstetric health. The study provides evidence that telehealth abortion is effective and safe, with rates similar to in-person care. The findings suggest that telehealth can expand access to abortion care, particularly for those in rural areas or with limited access to in-person care. The study also notes that telehealth models cannot serve everyone, such as those without electronic devices or those beyond the first trimester. The study is limited by the lack of clinic-level variation and potential selection bias due to follow-up rates. Overall, the study supports the use of telehealth for medication abortion, with similar effectiveness and safety to in-person care.A study on telehealth medication abortion in the USA found that it is effective and safe, with 97.7% of abortions being complete without further intervention. The study followed 6,034 patients who obtained medication abortion via telehealth from three virtual clinics across 20 states and Washington, DC. Safety was measured by the absence of serious adverse events, with 99.8% of abortions not resulting in such events. The effectiveness and safety were similar between synchronous and asynchronous models of care. The study also found that telehealth medication abortion is comparable to in-person care in terms of effectiveness and safety. The FDA removed the requirement for in-person dispensing of mifepristone in 2021, allowing for telehealth medication abortion. The study highlights the importance of telehealth in meeting increased demand for abortion care, especially in states with abortion bans. However, access to mifepristone is under threat, with a federal court ruling to reverse FDA regulatory approvals. The study also found that Black patients had higher rates of serious adverse events than white patients, highlighting disparities in obstetric health. The study provides evidence that telehealth abortion is effective and safe, with rates similar to in-person care. The findings suggest that telehealth can expand access to abortion care, particularly for those in rural areas or with limited access to in-person care. The study also notes that telehealth models cannot serve everyone, such as those without electronic devices or those beyond the first trimester. The study is limited by the lack of clinic-level variation and potential selection bias due to follow-up rates. Overall, the study supports the use of telehealth for medication abortion, with similar effectiveness and safety to in-person care.